Advertisement
Advertisement

More Related Content

Slideshows for you(20)

Similar to Current and future animal vaccine research activities at ILRI(20)

Advertisement

More from ILRI(20)

Advertisement

Current and future animal vaccine research activities at ILRI

  1. Current and future animal vaccine research activities at ILRI Vish Nene 8 International Congress on Ticks and Tick-Borne Pathogens (TTP8) and 12 Biennial Conference, South Africa, 24-29 August 2014
  2. Priority diseases targeted by the ILRI Vaccine Biosciences group Vaccines save lives and livestock and contribute to food security and poverty alleviation  African swine fever (ASF) – swine  African disease threatens the global $150 billion/year pig industry  Contagious bovine pleuropneumonia (CBPP) – cattle  Regional losses to CBPP amount to ~ $60 million/year  East Coast fever (ECF) – cattle  Regional losses exceed $300 million/year; kills ~ 1million cattle/year  Peste des petits ruminants (PPR) – small ruminants  Losses in Kenya alone amount to ~ $13 million/year  Rift Valley Fever (RVF) – small ruminants, cattle and human  2006/7 outbreak in Kenya cost ~ $30 million o 309 human cases in Kenya, Somalia and Tanzania; 140 deaths  Diagnostics are key components of a vaccine program  New and more user-friendly tests – evidence based control programs
  3. ILRI’s vaccine R & D pathway to impact Disease selec on Lead vaccine molecules Vaccine op miza on Scaled-up produc on Delivery Target product profile Phase I, II, III trials Regulatory processes Con nued monitoring  ILRI’s comparative advantage is mainly in the discovery phase to proof-of-principle under laboratory and field conditions.  Different entry points in pathway depending on disease targeted for control.  Improvement of existing vaccines  Development of subunit vaccines  Laboratory and field based diagnostics Marke ng Market assessment Proof-of-principle laboratory/field Clinical development Manufacturing Product development Research partnerships partnerships NARS, Universi es, ARIs, Regional and sub-regional R&D organiza ons, PPP PPP, Private sector, Regional networks, FAO, OIE, PANVAC, AU-IBAR, NARs, NGOs
  4. ILVAC – planting the orchard (ilvac.net) Vaccines are difficult to make and take time BASIC RESEARCH Increase our knowledge base “Knowledge lays the founda on for science & innova on” APPLIED RESEARCH Develop new vaccines & diagnos cs “Vaccines are highly effec ve an - disease interven ons” u Study host-pathogen interac ons u Map immune responses to infec on u Characterize pathogen virulence u Inves gate disease epidemiology u Dissect pathogen biology & diversity u Iden fy candidate vaccine and diagnos c molecules u Assess candidate vaccine molecules u Assess a enuated pathogens u Thermo-stabilize vaccines u Develop easy to use diagnos c tools u Assess different vaccina on systems u Facilitate transla on of research outputs to commercial products
  5. ILVAC - vaccine technologies (ilvac.net) Establish key principles in livestock vaccinology and capacity ILVAC – a vaccine pla orm An body technologies Cellular technologies Vaccine formula ons Genomic technologies Diagnos c technologies Contagious bovine pleuropneumonia East Coast fever African swine fever Consor a for research & product development and capacity development Private sector GALVmed CRPs NARS Inter-gov agencies Improved vaccines and diagnos c tools Peste des pe s ruminants Ri Valley fever Infec ous disease research: primary & applied
  6. The ILRI Vaccine Biosciences group
  7. Better lives through livestock ilri.org The presentation has a Creative Commons licence. You are free to re-use or distribute this work, provided credit is given to ILRI.

Editor's Notes

  1. Animals like humans suffer from infectious diseases There are existing vaccines against all these diseases expect ASF, but they are all sub-optimal in nature. ASF – no vaccine. Current control through diagnostics and slaughter; approach not viable in developing countries. Enhancing biosecurity can help. CBPP – duration of immunity is short lived and can cause side reactions ECF – live vaccine difficult to manufacture, needs liquid nitrogen cold chain and oxytetracycline co-treatment and costs 8~12 $/dose RVF – vaccine can cause abortions in sheep; difficult to know when to vaccinate because of epidemic nature of disease; human vaccine not available.
Advertisement